Damora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis

MT Newswires Live08-05

Damora Therapeutics (DMRA) said Wednesday it initiated a global Phase 1/1b clinical trial of DMR-001 in patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis.

The open-label, multicenter CLARITY-101 study will evaluate the safety, tolerability and preliminary efficacy of the investigational monoclonal antibody therapy.

The dose-escalation portion will begin with a 100-milligram monthly subcutaneous dose and is designed to identify a recommended dose for further development.

A planned expansion phase will assess DMR-001 in additional patient groups, earlier treatment settings and combinations with other therapies.

Damora expects to report initial trial data beginning in mid-2027, the biotechnology company said.

Price: 30.84, Change: +0.82, Percent Change: +2.71

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2657523027?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657523027","market":"us","top_or_hot":-1,"title":"Damora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis","media":"MT Newswires Live","content":"<html><body><p> Damora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (DMRA) said Wednesday it initiated a global Phase 1/1b clinical trial of DMR-001 in patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis.</p><p>The open-label, multicenter CLARITY-101 study will evaluate the safety, tolerability and preliminary efficacy of the investigational monoclonal antibody therapy.</p><p>The dose-escalation portion will begin with a 100-milligram monthly subcutaneous dose and is designed to identify a recommended dose for further development.</p><p>A planned expansion phase will assess DMR-001 in additional patient groups, earlier treatment settings and combinations with other therapies.</p><p>Damora expects to report initial trial data beginning in mid-2027, the biotechnology company said.</p><p>Price: 30.84, Change: +0.82, Percent Change: +2.71</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Damora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDamora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-05 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Damora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (DMRA) said Wednesday it initiated a global Phase 1/1b clinical trial of DMR-001 in patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis.</p><p>The open-label, multicenter CLARITY-101 study will evaluate the safety, tolerability and preliminary efficacy of the investigational monoclonal antibody therapy.</p><p>The dose-escalation portion will begin with a 100-milligram monthly subcutaneous dose and is designed to identify a recommended dose for further development.</p><p>A planned expansion phase will assess DMR-001 in additional patient groups, earlier treatment settings and combinations with other therapies.</p><p>Damora expects to report initial trial data beginning in mid-2027, the biotechnology company said.</p><p>Price: 30.84, Change: +0.82, Percent Change: +2.71</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2657523027","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657523027","pubTimestamp":1785940975,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Damora Therapeutics  said Wednesday it initiated a global Phase 1/1b clinical trial of DMR-001 in patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis.The open-label, multicenter CLARITY-101 study will evaluate the safety, tolerability and preliminary efficacy of the investigational monoclonal antibody therapy.The dose-escalation portion will begin with a 100-milligram monthly subcutaneous dose and is designed to identify a recommended dose for further development.A planned expansion phase will assess DMR-001 in additional patient groups, earlier treatment settings and combinations with other therapies.Damora expects to report initial trial data beginning in mid-2027, the biotechnology company said.Price: 30.84, Change: +0.82, Percent Change: +2.71","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","BK4144":"石油与天然气的储存和运输","BK4590":"PTP","BK4585":"ETF&股票定投概念","BK4139":"生物科技","UMI":"USCF Midstream Energy Income Fund","LENZ":"Therapeutics","MDST":"Westwood Salient Enhanced Midstream Income ETF","MLPA":"Global X MLP ETF","BK4106":"数据处理与外包服务","AMLP":"Alerian MLP ETF","BK4226":"数据处理及外包服务","AMZA":"InfraCap MLP ETF","TNGY":"Tortoise Energy Fund","ENFR":"Alerian Energy Infrastructure ET","BK4588":"碎股","EMLP":"第一信托北美能源基础设施基金","USAI":"Pacer American Energy Independence ETF","DMRA":"DAMORA THERAPEUT","XELA":"Exela Technologies, Inc.","EIPI":"FT Energy Income Partners Enhanced Income Etf","ET":"Energy Transfer LP","BK4007":"制药","EIPX":"FT ENERGY INCOME PARTNERS STRATEGY ETF","BK4539":"次新股","BK4561":"索罗斯持仓","TPZ":"Tortoise Electrification Infrastructure ETF"},"translate_title":"Damora Therapeutics 开始 DMR-001 治疗 ET、骨髓纤维化的试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UMI":0.6,"LENZ":1.5,"MDST":0.6,"AMZA":0.6,"EIPX":0.6,"DMRA":1,"AMLP":0.6,"EMLP":0.6,"EIPI":0.6,"XELA":1.5,"TNGY":0.6,"MLPA":0.6,"TPZ":0.6,"USAI":0.6,"ENFR":0.6,"ET":1.5},"content_text":"Damora Therapeutics (DMRA) said Wednesday it initiated a global Phase 1/1b clinical trial of DMR-001 in patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis.The open-label, multicenter CLARITY-101 study will evaluate the safety, tolerability and preliminary efficacy of the investigational monoclonal antibody therapy.The dose-escalation portion will begin with a 100-milligram monthly subcutaneous dose and is designed to identify a recommended dose for further development.A planned expansion phase will assess DMR-001 in additional patient groups, earlier treatment settings and combinations with other therapies.Damora expects to report initial trial data beginning in mid-2027, the biotechnology company said.Price: 30.84, Change: +0.82, Percent Change: +2.71","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657523027","isCrawlerRequest":true}